AI & TECH
OpenAI’s drug-development deal raises access questions
OpenAI’s Orchestra Bio acquisition adds agents that coordinate drug-development work across teams and outside partners.
OpenAI’s acquisition of Orchestra Bio adds a layer of coordination to its life-sciences tools, and puts a question of access in sharper focus. Orchestra’s agents organize development schedules, information and responses across company teams and outside research and manufacturing partners. OpenAI says scientists and program leaders will keep final decisions; the deal’s financial terms and integration date have not been disclosed.
Founded in fall 2022, Orchestra is joining GPT-Rosalind, OpenAI’s commercial biology product. OpenAI first released GPT-Rosalind as a research preview in April. The acquisition expands the company’s role from offering biology-focused AI tools to helping organize the work around drug development, without making OpenAI a drugmaker itself.
David Bennett argued that GPT-Rosalind’s restricted access for vetted U.S. enterprise customers, including Amgen and Moderna, could give large pharmaceutical companies an advantage over smaller drug developers. OpenAI also offers eligible university labs up to 30 free seats for 12 months. That plan widens access for some academic researchers, but does not resolve who can use the tools across the broader drug-development industry.
The question is also who shares in the value if the tools help produce a successful medicine. OpenAI CFO Sarah Friar has said licensing, intellectual-property agreements and outcome-based pricing could let the company capture some of that value. How those arrangements might work, and whether Orchestra’s agents will change access to GPT-Rosalind, remains unclear.